AGO TUMOR OPTIONS

Hormonal therapy remains the treatment of first choice for metastatic patients with endocrine-responsive breast cancer (LoE 1a A, Back ++). The sequential use in the readily available drugs depends upon the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of prognosis of relapse is usually recommended Every tim